IKZF2

IKZF2, which encodes the zinc-finger transcription factor Helios, belongs to the Ikaros family of transcriptional regulators that control hematopoietic and lymphoid cell gene programs through DNA binding and homo- or heterodimerization with related family members^[2][3]. Helios is most prominently associated with regulatory T-cell (Treg) biology, where it contributes to the maintenance of immune homeostasis by supporting a stable suppressive phenotype in both CD4⁺ and CD8⁺ regulatory T-cell populations^[1]. Mechanistically, Helios-dependent regulation is linked to sustained STAT5 pathway activity, preservation of FOXP3 expression, and restriction of inflammatory cytokine production, thereby maintaining Treg lineage stability during immune responses^[1]. In disease contexts, impaired Helios function disrupts regulatory T-cell activity and promotes autoimmune manifestations in experimental models, highlighting its importance in immune tolerance^[1]. In addition, elevated IKZF2 expression has been observed in advanced cutaneous T-cell lymphoma, where it promotes disease progression by inhibiting malignant-cell apoptosis and supporting immune-evasion mechanisms^[4]. Compared with related Ikaros family members such as IKZF1 (Ikaros), IKZF3 (Aiolos), and IKZF4 (Eos), Helios displays a particularly strong association with Treg stability and suppressive function, although all family members share conserved zinc-finger architecture and participate in immune-cell regulation^[2][3]. For experimental applications, IKZF2 has emerged as a therapeutic target in cancer immunology, and selective IKZF2 degraders have been developed to investigate Helios-directed immune modulation and antitumor responses^[5].